IP41-21: Evaluating Effect of Prior Checkpoint Inhibitor Exposure on Disease Control with Enfortumab Vedotin + Pembrolizumab in First Line Metastatic Bladder Cancer

IP41-21: Evaluating Effect of Prior Checkpoint Inhibitor Exposure on Disease Control with Enfortumab Vedotin + Pembrolizumab in First Line Metastatic Bladder Cancer

Saturday, May 16, 2026 1:00 PM to 3:00 PM · 1 hr. 59 min. (America/New_York)
147A
Abstract

Log in

See all the content and easy-to-use features by logging in or registering!